. 2016 Jan 22;27(4):648–653. doi: 10.1093/annonc/mdw020

Table 1.

Efficacy as a function of best PET response

Efficacy	nab-P + Gem				Gem
	PET response		RRR or HR^a (95% CI)	P value	PET response		RRR or HR^a (95% CI)	P value
	Yes (N = 93)	No (N = 37)	RRR or HR^a (95% CI)	P value	Yes (N = 67)	No (N = 60)	RRR or HR^a (95% CI)	P value
ORR by RECIST	37%	16%	2.3 (1.03–4.92)	0.023	18%	3%	5.4 (1.25–23.04)	0.009
Median PFS	7.5 months	5.3 months	0.63 (0.36–1.11)	0.110	5.6 months	3.6 months	0.39 (0.24–0.66)	<0.001
Median OS	11.5 months	8.0 months	0.85 (0.54–1.32)	0.464	10.9 months	6.3 months	0.43 (0.29–0.65)	<0.001

^aRRR = ORR_{PET response}/ORR_{no PET response}; HR = HR_{PET response}/_{no PET response.}

Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxel; ORR, overall response rate; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors; RRR, response rate ratio.